irinotecan has been researched along with tamoxifen in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Blanchette, RA; Dahse, HM; Hoffmeister, D; Horn, U; Nett, M; Schwenk, D | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, TC; Fry, D; Liebes, L; Su, S | 1 |
| Algeciras-Schimnich, A; O'Kane, DJ; Snozek, CL | 1 |
| Lee, SY; McLeod, HL | 1 |
| Sai, K; Saito, Y | 1 |
| Begg, EJ; Helsby, NA; Jensen, BP | 1 |
| Coward, L; Darby, A; Gorman, GS; Rasberry, B | 1 |
| Coward, L; Gorman, G; Grappe, F; Nance, G | 1 |
| Ise, Y; Kitagawa, C; Saka, H | 1 |
| Li, FY; Liu, L; Liu, ZQ; Lu, L; Peng, XJ; Qi, XX; Shi, J; Wang, Y; Zhou, FY; Zhou, J | 1 |
| Guo, GL; Schumacher, JD | 1 |
| Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J | 1 |
7 review(s) available for irinotecan and tamoxifen
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacogenomics of tamoxifen and irinotecan therapies.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen; Treatment Outcome | 2008 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Tamoxifen | 2011 |
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Ethnicity; Gemcitabine; Genetic Markers; Genotype; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Polymorphism, Single Nucleotide; Tamoxifen | 2011 |
Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.
Topics: Aryl Hydrocarbon Hydroxylases; Azathioprine; Camptothecin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Enzymes; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Methyltransferases; Mixed Function Oxygenases; Prodrugs; Tamoxifen; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin | 2012 |
Mechanistic review of drug-induced steatohepatitis.
Topics: Amiodarone; Animals; Camptothecin; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fatty Liver; Hepatocytes; Humans; Irinotecan; Lipid Metabolism; Liver; Methotrexate; Mitochondria, Liver; Organoplatinum Compounds; Oxaliplatin; Perhexiline; Tamoxifen; Tetracycline; Valproic Acid | 2015 |
14 other study(ies) available for irinotecan and tamoxifen
| Article | Year |
|---|---|
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Injury-induced biosynthesis of methyl-branched polyene pigments in a white-rotting basidiomycete.
Topics: Animals; Basidiomycota; Dose-Response Relationship, Drug; Drosophila melanogaster; Electron Spin Resonance Spectroscopy; Humans; K562 Cells; Larva; Methionine; Molecular Structure; Pigments, Biological; Polyenes; S-Adenosylmethionine; Stereoisomerism | 2014 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Camptothecin; Cell Line; Glioblastoma; Humans; Irinotecan; Naphthalenes; Perylene; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 2003 |
Effects of herbal supplements on the bioactivation of chemotherapeutic agents.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Cimicifuga; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Hypericum; Inhibitory Concentration 50; Irinotecan; Microsomes, Liver; Plant Extracts; Regression Analysis; Tamoxifen; Tandem Mass Spectrometry; Zingiber officinale | 2013 |
In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism.
Topics: Camptothecin; Dose-Response Relationship, Drug; Herb-Drug Interactions; Humans; Irinotecan; Microsomes, Liver; Plant Preparations; Tamoxifen | 2014 |
[Biomarkers for the prediction of adverse events].
Topics: Antineoplastic Agents; Biomarkers; Camptothecin; Fluorouracil; Humans; Irinotecan; Mercaptopurine; Tamoxifen | 2015 |
Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients.
Topics: Adult; Camptothecin; Carcinoma, Hepatocellular; Genistein; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Liver Neoplasms; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Propofol; Tamoxifen; Zidovudine | 2015 |
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |